557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial

Patrizia Froesch, Martin Früh, Q. Li et al.|Annals of Oncology|2020

Cited by 1